Aptahem » News

Aptahem strengthens the company´s scientific advisory board with internationally recognised and highly qualified experts in advancement of clinical studies

2018-01-17

Aptahem is today pleased to announce the recruitment to the company´s scientific advisory board of Hans Peter Schwarz and Mats Eriksson; two highly experienced and internationally recognised experts. Professor Hans Peter Schwarz, MD has previously held leading positions within...

Aptahem has finalized an improved bioanalytical method for the measurement of Apta-1 in plasma

2017-12-20

Aptahem is now able to announce that the development of a completely new bioanalysis method has been finalized in collaboration with our partner Axolab in Germany. The new method has a better resolution and can detect lower levels of...

Interview with the Chairman of the Scientific Advisory Board, Dr Anders Bylock

2017-11-10

”Aptahem’s drug candidate shows sensationally good results in sepsis studies” The scientific advisory board has now been in place for almost a year, and we have interviewed the president of the board, Dr. Anders Bylock, about what has happened...

Aptahem submits patent application based on new results, drafts a prospectus supplement and extends subscription period

2017-10-03

Aptahem (publ) announced today that the company has submitted a new patent application based on the latest research results of Apta-1, with the aim of strengthening the company’s intellectual property rights portfolio. The new patent application is based on...

Apta-1 shows improved survival rate in extended study

2017-09-12

Aptahem (publ) can announce today new positive results from an extended study performed with Hooke Laboratories (US), the collaborating partner. The results show that intravenous administration of Apta-1 correlates with an improved survival rate in test animals. The outcome...

Aptahem presents a new development plan for Apta-1

2017-08-11

Aptahem AB (publ) can announce today that the company’s board has finalized a revised development plan for the drug candidate Apta-1. The new development plan was established together with the company’s scientific advisory board who assessed Apta-1’s pharmacological properties....

Aptahem enters into production agreement with BioSpring

2017-08-10

Aptahem AB (publ) can announce today that it has entered into a production agreement with BioSpring, a world-leading producer of oligonucleotides. BioSpring has been contracted to manufacture the substance in drug candidate Apta-1 for the company’s preclinical and upcoming...

Apta-1 improves survival rate and blood circulation in a clinical model relevant for sepsis

2017-07-28

Aptahem (publ) can today announce a positive outcome from a study performed in collaboration with Hooke Laboratories (US). The study evaluated the pharmaceutical candidate Apta-1 in a clinically relevant model for sepsis which showed a significant improvement in survival...

Aptahem adjusts the schedule and capital requirements as a result of the decision to update the clinical development strategy

2017-04-03

Aptahem’s preclinical programme is proceeding with the gradual collection of data on the Apta-1 effect profile, while the work on the company’s clinical development is proceeding in consultation with external experts. Dialogue with opinion leaders and potential partners has...

Aptahem strengthens its research and development organisation with industrial expertise in cardiovascular diseases and clinical development

2017-02-07

Aptahem can today announce that it has entered into an agreement with lecturer and registered practitioner Anders Bylock, a well-known expert on issues related to cardiovascular treatment including pre-clinical development, clinical trials and regulatory submissions. Dr Bylock will provide...